RT Journal Article
SR Electronic
T1 Immune memory in mild COVID-19 patients and unexposed donors from India reveals persistent T cell responses after SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.16.20232967
DO 10.1101/2020.11.16.20232967
A1 Ansari, Asgar
A1 Arya, Rakesh
A1 Sachan, Shilpa
A1 Jha, Someshwar Nath
A1 Kalia, Anurag
A1 Lall, Anupam
A1 Sette, Alessandro
A1 Grifoni, Alba
A1 Weiskopf, Daniela
A1 Coshic, Poonam
A1 Sharma, Ashok
A1 Gupta, Nimesh
YR 2021
UL http://medrxiv.org/content/early/2021/02/26/2020.11.16.20232967.abstract
AB Understanding the causes of the diverse outcome of COVID-19 pandemic in different geographical locations is important for the worldwide vaccine implementation and pandemic control responses. We analyzed 42 unexposed healthy donors and 28 mild COVID-19 subjects up to 5 months from the recovery for SARS-CoV-2 specific immunological memory. Using HLA class II predicted peptide megapools, we identified SARS-CoV-2 cross-reactive CD4+ T cells in around 66% of the unexposed individuals. Moreover, we found detectable immune memory in mild COVID-19 patients several months after recovery in the crucial arms of protective adaptive immunity; CD4+ T cells and B cells, with a minimal contribution from CD8+ T cells. Interestingly, the persistent immune memory in COVID-19 patients is predominantly targeted towards the Spike glycoprotein of the SARS-CoV-2. This study provides the evidence of both high magnitude pre-existing and persistent immune memory in Indian population. By providing the knowledge on cellular immune responses to SARS-CoV-2, our work has implication for the development and implementation of vaccines against COVID-19.Competing Interest StatementA.S is listed as inventor on patent application no. 63/012,902, submitted by La Jolla Institute for Immunology, that covers the use of the megapools and peptides thereof for therapeutic and diagnostic purposes. A.S. is a consultant for Gritstone, Flow Pharma, Merck, Epitogenesis, Gilead and Avalia. Other authors declared no commercial or financial conflicts of interest.Funding StatementThis work was supported by Science and Engineering Research Board, DST grant IPA/2020/000077 (to NG, AS, PC), Biotechnology Industry Research Assistance Council, DBT grant BT/COVID0010/01/20 (to NG). Further support provided from NIH contract 75N9301900065 (to A.S, D.W) and NIH grant U01 (U01AI141995-03) to A.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional review boards of the National Institute of Immunology and All India Institute of Medical Sciences, New Delhi, India. Informed consent was obtained from all subjects during the enrolment. For analyses in healthy individuals, buffy coat and plasma samples isolated from blood of healthy donors were collected from the blood bank in All India Institute of Medical Sciences, New Delhi, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot Applicable